EntryPoint Capital’s Cytek Biosciences CTKB Stock Holding History

EntryPoint Capital’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-47,746	Closed	-$162K	–	710
2025 Q2	$162K	Buy	+47,746	New	+$159K	0.08%	523
2024 Q4	–	Sell	-51,030	Closed	-$283K	–	773
2024 Q3	$283K	Buy	+51,030	New	+$289K	0.16%	274
2024 Q1	–	Sell	-9,567	Closed	-$87.3K	–	1485
2023 Q4	$87.3K	Buy	+9,567	New	+$60.2K	0.08%	446

Other funds holding CTKB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EntryPoint Capital's CTKB Position: Q3 2025 in Review

EntryPoint Capital sold out of Cytek Biosciences (CTKB) in Q3 2025, closing a stake of 47,746 shares — an estimated $162K sold.

EntryPoint Capital first reported a position in CTKB in Q4 2023 and held it in 3 quarters. The position peaked at $283K in Q3 2024. 153 funds tracked by Wall St. Rank hold CTKB as of Q3 2025.

EntryPoint Capital reported no remaining Cytek Biosciences position as of Q3 2025 after selling out during the quarter.
EntryPoint Capital sold 47,746 Cytek Biosciences shares in Q3 2025, an estimated $162K.
EntryPoint Capital first reported a position in Cytek Biosciences in Q4 2023 and held it in 3 quarters.
EntryPoint Capital's Cytek Biosciences position peaked at $283K in Q3 2024.
153 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2025.

Based on EntryPoint Capital's 13F filing for Q3 2025, filed 13 Nov 2025.